Home | Welcome to Contract Pharma   
Last Updated Sunday, May 24 2015

Print RSS Feed

WuXi PharmaTech Begins HPAPI Ops

Published May 28, 2014
WuXi PharmaTech’s manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd. (STA), has begun operations for a high-potency active pharmaceutical ingredient (HPAPI) at its lab in Shanghai. The lab has added HPAPI processing to its portfolio of services to support process development and clinical trial supply of high-potency small molecules at kilogram scale.
"With the increasing use of HPAPIs in drug discovery and development, this new service augments WuXi's ability to provide highly efficient and cost-effective solutions for our partners worldwide," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On